Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions

被引:15
作者
Cabana, M [1 ]
Fernàndez, G [1 ]
Parera, M [1 ]
Clotet, B [1 ]
Martínez, MA [1 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, Lab Retrovirol, Fdn IrsiCaixa, Badalona, Spain
关键词
bacteriophage; lambda; genetic screen system; HIV-1; protease primary resistance mutations;
D O I
10.1006/viro.2002.1520
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have shown that a bacteriophage lambda genetic screen system may be useful in predicting the activity and phenotype of HIV-1 protease in the course of viral infection and antiretroviral therapy. This simple and rapid genetic screening system has been used here to characterize HIV-1 proteases encoding single primary resistance substitutions. Except for proteases with amino acid changes at positions 46 and 84, proteases containing single-resistance substitutions displayed a lower catalytic efficiency than the WT enzyme. Single mutants could be identified by their efficiency, demonstrating that modest differences in protease activity can be monitored with this simple assay. Overall, drug susceptibility could be reduced by introduction of single mutations. However, high-level protease inhibitor (PI) resistance was only achieved by multiple mutated proteases. The small but reproducible increase in resistance displayed by single mutants also demonstrated the ability of this genetic screen system for detecting minor reductions in drug susceptibility. These results show that the bacteriophage lambda genetic screen system used here is a useful tool in the analysis of specific contribution of mutations in the HIV protease-coding region or in specific cleavage sites that affect the process of PI resistance. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:71 / 78
页数:8
相关论文
共 53 条
  • [1] Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine
    Atkinson, B
    Isaacson, J
    Knowles, M
    Mazabel, E
    Patick, AK
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (02) : 420 - 427
  • [2] Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors
    Bally, F
    Martinez, R
    Peters, S
    Sudre, P
    Telenti, A
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (13) : 1209 - 1213
  • [3] Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
    Bleiber, G
    Munoz, M
    Ciuffi, A
    Meylan, P
    Telenti, A
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (07) : 3291 - 3300
  • [4] Resistance to human immunodeficiency virus type 1 protease inhibitors
    Boden, D
    Markowitz, M
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 2775 - 2783
  • [5] Cabana M, 1999, J MED VIROL, V59, P480, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt
  • [6] 480::AID-JMV10&gt
  • [7] 3.0.CO
  • [8] 2-8
  • [9] Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel
    Carpenter, CCJ
    Cooper, DA
    Fischl, MA
    Gatell, JM
    Gazzard, BG
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schechter, M
    Schooley, RT
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03): : 381 - 390
  • [10] In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
    Carrillo, A
    Stewart, KD
    Sham, HL
    Norbeck, DW
    Kohlbrenner, WE
    Leonard, JM
    Kempf, DJ
    Molla, A
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (09) : 7532 - 7541